The evolving landscape of therapeutic drug development for hepatocellular carcinoma

Area of Science:

• Oncology
• Translational Medicine
• Genomics

Background:

• Advanced hepatocellular carcinoma (HCC) has limited FDA-approved treatments, with sorafenib offering modest efficacy.
• Unlike other cancers, HCC lacks validated oncogenic addiction targets for therapy.
• Improving HCC outcomes necessitates identifying molecular subclasses, predictive biomarkers, and therapeutic drivers.

Purpose of the Study:

• To explore the molecular heterogeneity of hepatocellular carcinoma.
• To develop patient-derived xenograft (PDX) models for pre-clinical drug development in specific HCC molecular subgroups.
• To identify novel therapeutic vulnerabilities and drug synergies in diverse HCC models.

Main Methods:

• Development of a panel of patient-derived xenograft (PDX) models representing molecularly diverse HCC.
• Pre-clinical drug screening and evaluation of therapeutic responses across these PDX models.
• Analysis of drug activity patterns, including synergistic effects, within specific molecular subgroups.

Main Results:

• Observed unique patterns of drug activity and synergistic effects across diverse HCC xenografts.
• Identified specific therapeutic vulnerabilities tailored to individual molecularly defined tumors.
• Demonstrated the utility of PDX models for pre-clinical drug development in HCC.

Conclusions:

• Molecular subtyping and PDX models are essential for advancing HCC therapeutics.
• Targeted therapies and rational drug design can exploit identified vulnerabilities for improved patient outcomes.
• Strategic patient allocation into enriched clinical trials is critical for optimizing treatment development.